1. Home
  2. XGN vs STIM Comparison

XGN vs STIM Comparison

Compare XGN & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exagen Inc.

XGN

Exagen Inc.

N/A

Current Price

$8.46

Market Cap

110.7M

Sector

Health Care

ML Signal

N/A

Logo Neuronetics Inc.

STIM

Neuronetics Inc.

N/A

Current Price

$2.14

Market Cap

120.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XGN
STIM
Founded
2002
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.7M
120.4M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
XGN
STIM
Price
$8.46
$2.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
4
Target Price
★ $10.14
$5.75
AVG Volume (30 Days)
273.4K
★ 1.1M
Earning Date
11-03-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 57.25
EPS
N/A
★ N/A
Revenue
N/A
★ $52,776,000.00
Revenue This Year
$11.02
$8.63
Revenue Next Year
$10.28
$9.24
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.59
$0.80
52 Week High
$12.23
$3.44

Technical Indicators

Market Signals
Indicator
XGN
STIM
Relative Strength Index (RSI) 58.90 29.28
Support Level $7.81 $1.99
Resistance Level $8.89 $2.13
Average True Range (ATR) 0.42 0.13
MACD -0.07 -0.06
Stochastic Oscillator 58.33 2.31

Price Performance

Historical Comparison
XGN
STIM

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

About STIM Neuronetics Inc.

Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.

Share on Social Networks: